Latest News

Neoadjuvant enfortumab vedotin plus pembrolizumab significantly improved event-free survival and overall survival compared with gemcitabine plus cisplatin.

In an interview, C. Ola Landgren, MD, PhD, delved into the details of the FDA's draft guidance on using MRD as a basis for FDA approvals in multiple myeloma.

Clinical trial data show ovarian cancer survival gaps narrow with diverse enrollment, but disparities persist after progression, spotlighting access, toxicity, and care barriers.

Findings from the phase 1 PAnTHA study demonstrate that actinium-225 was well tolerated with encouraging responses in patients with metastatic castration-resistant prostate cancer.

PEACE-3 data show enzalutamide plus radium-223 extends survival and delays progression in bone-predominant mCRPC, with manageable added toxicity.

During a live event, Joshua Richter, MD, discussed dosing strategies when using selinexor in relapsed/refractory multiple myeloma.

The phase 2 BRCAAway trial demonstrated that abiraterone acetate, prednisone, and olaparib significantly improves progression-free survival and overall survival compared with either agent used alone or sequentially in patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 or ATM alterations.

FDA clears zongertinib for HER2-mutant advanced nonsquamous NSCLC, showing strong responses and promising brain metastasis activity.

Tumor-infiltrating lymphocyte therapy yielded favorable results in a small cohort of patients with soft tissue sarcoma, leading to plans for a larger trial.

Experts discuss the SWOG S1512 trial of desmoplastic melanoma and the greater relevance of trials of immunotherapy in rare disease states.

The first patient was treated in a study of continuous subcutaneous administration of lenalidomide in multiple myeloma.

BCMA bispecific teclistamab delivers 63% responses and durable remissions in heavily pretreated myeloma, with new infection prophylaxis insights.

FDA confirms first-line BRAF V600E mCRC gains: encorafenib plus cetuximab with FOLFOX or FOLFIRI improves PFS and OS.

FDA fast tracks ART6043, an oral Polθ inhibitor for gBRCA HER2-negative metastatic breast cancer, showing early activity and potential to overcome PARP resistance.

During a live event, Daniel Olson, MD, discussed data and experience using tumor-infiltrating lymphocytes in melanoma.

Highlights from the 2026 ASCO Genitourinary Cancer Symposium featuring key presentations in bladder, kidney, prostate, and rare cancers.

Cross-trial analysis shows zanubrutinib delivers longer progression-free survival than ibrutinib or acalabrutinib in relapsed CLL, including high-risk del(17p)/del(11q).

The NCCN guidelines now include the Merlin CP-GEP assay as part of shared decision-making for a sentinel lymph node biopsy in patients with melanoma.

Explore this week’s oncology breakthroughs: genomic-driven lung cancer care, record survival gains, and FDA moves in myeloma and subcutaneous amivantamab.

Preclinical and early clinical data showed that a proteasome inhibitor could increase BCMA expression after failure of CAR T-cell therapy.

Phase 2 data show elenagen plus gemcitabine extends survival in platinum-resistant ovarian cancer with high CA-125, without added toxicity.

RB-1355 reprograms autologous macrophages to heat up lymphoma tumors, avoid lymphodepletion, and deliver fast 1-week cellular therapy.

FDA fast-tracks PLT012, a CD36 metabolic checkpoint antibody for liver cancer, as phase 1 trial tests safety and early efficacy.

Electronic symptom reports plus pediatric palliative care improve physical quality of life in advanced childhood cancer when follow-up is consistent.

FDA reviews oral giredestrant plus everolimus for ESR1-mutated ER+ metastatic breast cancer after CDK4/6 failure, with strong PFS gains and manageable safety.

FDA approves 14‑month, all‑oral acalabrutinib plus venetoclax first-line for CLL/SLL, boosting progression-free survival and offering a fixed-duration alternative to chemo.

During a Case-Based Roundtable event, Timothy Cloughesy, MD, and participants discuss targeted IDH inhibition in patients with grade 2 gliomas.

An overview of the FDA’s draft guidance on MRD as a clinical trial end point, with expert insight on what it means for drug development in multiple myeloma.

Discover how AI accelerates precision cancer care, streamlines trials, and tackles bias and liability—what oncologists need to know now.

Screening rates fall as many women seek privacy and convenience; FDA‑cleared home HPV self-sampling may boost access and reduce disparities.

Durvalumab boosts survival in limited-stage SCLC, yet US costs miss value thresholds, fueling urgent debates on access and pricing.